539 related articles for article (PubMed ID: 27007464)
21. Different prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers.
Abd El-Hafez A; Shawky Mohamed Ael-A; Elesawy BH
Asian Pac J Cancer Prev; 2013; 14(2):1037-41. PubMed ID: 23621182
[TBL] [Abstract][Full Text] [Related]
22. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
[TBL] [Abstract][Full Text] [Related]
23. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
25. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
26. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
Qian J; Ma Y; Tahaney WM; Moyer CL; Lanier A; Hill J; Coleman D; Koupaei N; Hilsenbeck SG; Savage MI; Page BDG; Mazumdar A; Brown PH
Breast Cancer Res; 2024 Feb; 26(1):23. PubMed ID: 38317231
[TBL] [Abstract][Full Text] [Related]
27. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
30. Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo.
Lothstein L; Soberman J; Parke D; Gandhi J; Sweatman T; Seagroves T
Oncol Res; 2020 Dec; 28(5):451-465. PubMed ID: 32430093
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
32. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
33. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
34. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
[TBL] [Abstract][Full Text] [Related]
35. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer.
Li X; Strietz J; Bleilevens A; Stickeler E; Maurer J
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936348
[TBL] [Abstract][Full Text] [Related]
37. Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams.
Cammarata FP; Forte GI; Broggi G; Bravatà V; Minafra L; Pisciotta P; Calvaruso M; Tringali R; Tomasello B; Torrisi F; Petringa G; Cirrone GAP; Cuttone G; Acquaviva R; Caltabiano R; Russo G
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882850
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer.
Cui Y; Huang Y; Wu X; Zheng M; Xia Y; Fu Z; Ge H; Wang S; Xie H
J Cell Physiol; 2019 Jun; 234(6):8740-8751. PubMed ID: 30362543
[TBL] [Abstract][Full Text] [Related]
39. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
40. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.
Banda M; Speyer CL; Semma SN; Osuala KO; Kounalakis N; Torres Torres KE; Barnard NJ; Kim HJ; Sloane BF; Miller FR; Goydos JS; Gorski DH
PLoS One; 2014; 9(1):e81126. PubMed ID: 24404125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
